Malvern, PA – According to filings with the U.S. Securities and Exchange Commission, Ocugen is raising $14,283,724.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Shankar Musunuri played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Ocugen
Ocugen, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to treat the whole eye. Our Phase 3 small molecule drug candidate for oGVHD, if approved, will be the first and only treatment for this orphan disease. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug one to many. And our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy.

To learn more about Ocugen, visit http://www.ocugen.com/

Contact:
Shankar Musunuri, Chief Executive Officer
484-328-4698
shankar.musunuri@ocugen.com
https://www.linkedin.com/in/shankarmusunuri/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved